Table 2.
Mean peak, trough, or single values (95% CI) of measures in which there was a significant Sex × Dose interaction. Estimates are adjusted for drinking group and weight.
| Oxycodone Dose | |||||
|---|---|---|---|---|---|
| Response Variablea | Subgroup | placebo | 10 mg | 20 mg | p-value for Dose effect |
| ARCI | |||||
| LSD (range: 0-14) | males: | 3.81 (2.88, 4.75) | 4.81 (3.88, 5.75) * | 5.25 (4.32, 6.18) **, § | 0.05 |
| females: | 3.60 (2.56, 4.64) | 6.37 (5.33, 7.41) ‡ | 7.60 (6.56, 8.64) ‡ | <0.0001 | |
| VAS (range: 0-100) | |||||
| Dizzy | males: | 1.38 (-11.13, 13.88) | 12.44 (-0.07, 24.94) | 15.94 (3.43, 28.44) ** | 0.11 |
| females: | 10.58 (-3.30, 24.47) | 37.74 (23.85, 51.63) ‡ | 55.05 (41.16, 68.93) ‡ | <0.0001 | |
| Feel bad | males: | 7.56 (-3.53, 18.65) | 11.31 (0.22, 22.40) | 17.56 (6.47, 28.65) *** | 0.43 |
| females: | 9.52 (-2.79, 21.84) | 33.06 (20.75, 45.37) † | 63.14 (50.82, 75.45) ‡ | <0.0001 | |
| Heavy, sluggish feeling | males: | 13.94 (-1.11, 28.98) | 24.38 (9.33, 39.42) | 38.63 (23.58, 53.67) * † | 0.01 |
| females: | 20.50 (3.80, 37.21) | 44.66 (27.95, 61.37) † | 77.04 (60.33, 93.75) ‡ | <0.0001 | |
| In control of bodyb | males: | 80.63 (67.12, 94.13) | 75.13 (61.62, 88.63) | 60.44 (46.93, 73.95) † | 0.03 |
| females: | 94.62 (79.62, 109.6) | 62.70 (47.70, 77.70) ‡ | 43.70 (28.70, 58.70) ‡ | <0.0001 | |
| Nauseated | males: | 2.19 (-9.90, 14.27) | 9.88 (-2.21, 21.96) | 17.88 (5.79, 29.96) *** | 0.11 |
| females: | 1.47 (-11.94, 14.89) | 28.40 (14.98, 41.82) ‡ | 60.17 (46.75, 73.59) ‡ | <0.0001 | |
| Unpleasant bodily sensations | males: | 6.50 (-4.70, 17.70) | 12.88 (1.68, 24.07) | 17.25 (6.05, 28.45) *** | 0.32 |
| females: | 9.77 (-2.66, 22.21) | 30.24 (17.80, 42.67) † | 59.16 (46.73, 71.59) ‡ | <0.0001 | |
| OARS (range: 0-4) | |||||
| Turning of stomach | males: | 0.38 (-0.08, 0.83) | 0.63 (0.17, 1.08) | 0.56 (0.11, 1.02) *** | 0.67 |
| females: | 0.53 (0.02, 1.03) | 1.07 (0.56, 1.57) | 2.68 (2.18, 3.18) ‡ | <0.0001 | |
| DEL/TA | |||||
| Like drugb,c | males: | 47.44 (40.61, 54.26) | 43.00 (36.18, 49.82) *** | 34.00 (27.18, 40.82)***, † | 0.02 |
| females: | 43.34 (35.76, 50.91) | 20.49 (12.92, 28.07) ‡ | 13.18 (5.61, 20.76) ‡ | <0.0001 | |
| Take drug againb,d | males: | 49.56 (42.01, 57.11) | 48.56 (41.01, 56.11)*** | 34.13 (26.57, 41.68)*, † | 0.005 |
| females: | 45.94 (37.56, 54.32) | 22.33 (13.94, 30.71) ‡ | 18.48 (10.10, 26.86) ‡ | <0.0001 | |
| End-of-session DEL/TAe | |||||
| Like drugf | males: | 51.94 (42.69, 61.19) | 56.38 (47.13, 65.62)** | 50.31 (41.06, 59.56) ** | 0.59 |
| females: | 48.53 (38.26, 58.80) | 31.53 (21.26, 41.80) § | 26.69 (16.42, 36.95) ‡ | 0.004 | |
| Take drug againd,g | males: | 53.31 (41.48, 65.14) | 59.88 (48.04, 71.71)* | 46.56 (34.73, 58.39) | 0.26 |
| females: | 53.05 (39.92, 66.19) | 33.98 (20.84, 47.11) § | 28.59 (15.46, 41.73) † | 0.02 | |
Abbreviations:ARCI = Addiction Research Center Inventory; LSD = Lysergic Acid Diethylamide scale; VAS = Visual Analog Scale; OARS = Opiate Adjective Rating Scale; DEL/TA = Drug Effect/Drug Liking/Take Again questionnaire
All measures are peak measures unless noted otherwise
Trough measure
Range:0-100, 0=dislike a lot; 50=neutral; 100=like a lot
Range: 0-100, 0=definitely would not; 50=neutral (don't care); 100=definitely would
Mean measures
Range: 0-100, 0=disliked a lot; 50=neutral; 100=liked a lot
Sex × Dose interaction non-significant (p=0.10); shown for comparison to in-session DEL/TA measures and end-of-session drug liking. In main effects model for this outcome: Sex p=0.06, Dose p=0.055
Active dose comparison vs. 0 mg dose:
p≤0.001,
p≤0.01,
p≤0.05
Sex comparison:
p≤0.001,
p≤0.01,
p≤0.05